Shire faces criticism on CEO pay policy as crunch week looms

LONDON (Reuters) - Shire , the $47 billion rare disease drugmaker being stalked by Japan's Takeda Pharmaceutical , faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches.

Shire faces criticism on CEO pay policy as crunch week looms
Read More


Bagikan Berita Ini